Esperion Therapeutics (ESPR) Earning Somewhat Favorable News Coverage, Accern Reports
Media stories about Esperion Therapeutics (NASDAQ:ESPR) have trended somewhat positive on Thursday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Esperion Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.2300084979545 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Chardan Capital Increases Esperion Therapeutics (ESPR) Price Target to $75.00 (americanbankingnews.com)
- Esperion Therapeutics’ (ESPR) Hold Rating Reiterated at Chardan Capital (americanbankingnews.com)
- 3 Stocks That Quadrupled (finance.yahoo.com)
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Nasdaq:ESPR (menafn.com)
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) – GlobeNewswire (press release) (globenewswire.com)
Shares of Esperion Therapeutics (ESPR) opened at $53.14 on Thursday. Esperion Therapeutics has a 52-week low of $10.71 and a 52-week high of $65.20.
Several analysts recently issued reports on ESPR shares. Chardan Capital increased their price target on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the stock a “neutral” rating in a research report on Wednesday. Northland Securities began coverage on shares of Esperion Therapeutics in a research report on Tuesday, August 29th. They issued an “outperform” rating and a $72.00 target price on the stock. Jefferies Group restated a “buy” rating and issued a $85.00 target price on shares of Esperion Therapeutics in a research report on Monday, August 21st. Zacks Investment Research upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Finally, Cowen began coverage on shares of Esperion Therapeutics in a research report on Thursday, September 7th. They issued an “outperform” rating and a $64.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Esperion Therapeutics has an average rating of “Buy” and an average target price of $60.15.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/07/esperion-therapeutics-espr-earning-somewhat-favorable-news-coverage-accern-reports.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.